Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder in which complex genetic factors play an important role. Several strains of gene-targeted mice have been reported to develop SLE, implicating the null genes in the causation of disease. However, hybrid strains between 129 and C57BL/6 mice, widely used in the generation of gene-targeted mice, develop spontaneous autoimmunity. Furthermore, the genetic background markedly influences the autoimmune phenotype of SLE in gene-targeted mice. This suggests an important role in the expression of autoimmunity of as-yet-uncharacterised background genes originating from these parental mouse strains. Using genome-wide linkage analysis, we identified several susceptibility loci, derived from 129 and C57BL/6 mice, mapped in the lupus-prone hybrid (129 × C57BL/6) model. By creating a C57BL/6 congenic strain carrying a 129-derived Chromosome 1 segment, we found that this 129 interval was sufficient to mediate the loss of tolerance to nuclear antigens, which had previously been attributed to a disrupted gene. These results demonstrate important epistatic modifiers of autoimmunity in 129 and C57BL/6 mouse strains, widely used in gene targeting. These background gene influences may account for some, or even all, of the autoimmune traits described in some gene-targeted models of SLE.
References
[1]
Baltz ML, Gomer K, Davies AJ, Evans DJ, Klaus GG, et al. (1980) Differences in the acute phase responses of serum amyloid P-component (SAP) and C3 to injections of casein or bovine serum albumin in amyloid-susceptible and -resistant mouse strains. Clin Exp Immunol 39: 355–360.
[2]
Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Tennent GA, et al. (1999) Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 5: 694–697.
[3]
Bolland S, Ravetch JV (2000) Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity 13: 277–285.
[4]
Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, et al. (1997) Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 3: 855–859.
[5]
Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, et al. (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 19: 56–59.
[6]
Breathnach SM, Kofler H, Sepp N, Ashworth J, Woodrow D, et al. (1989) Serum amyloid P component binds to cell nuclei in vitro and to in vivo deposits of extracellular chromatin in systemic lupus erythematosus. J Exp Med 170: 1433–1438.
[7]
Butler PJ, Tennent GA, Pepys MB (1990) Pentraxin–chromatin interactions: Serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin. J Exp Med 172: 13–18.
[8]
Drake CG, Rozzo SJ, Hirschfeld HF, Smarnworawong NP, Palmer E, et al. (1995) Analysis of the New Zealand Black contribution to lupus-like renal disease: Multiple genes that operate in a threshold manner. J Immunol 154: 2441–2447.
[9]
Drake CG, Rozzo SJ, Vyse TJ, Kotzin BL (1996) Absence of coding sequence polymorphism in the serum amyloid P component gene (Sap) in autoimmune New Zealand black mice. Mamm Genome 7: 466–467.
[10]
Familian A, Zwart B, Huisman HG, Rensink I, Roem D, et al. (2001) Chromatin-independent binding of serum amyloid P component to apoptotic cells. J Immunol 167: 647–654.
[11]
Harley JB, Moser KL, Gaffney PM, Behrens TW (1998) The genetics of human systemic lupus erythematosus. Curr Opin Immunol 10: 690–696.
[12]
Haywood ME, Hogarth MB, Slingsby JH, Rose SJ, Allen PJ, et al. (2000) Identification of intervals on chromosomes 1, 3, and 13 linked to the development of lupus in BXSB mice. Arthritis Rheum 43: 349–355.
[13]
Hintner H, Booker J, Ashworth J, Aubock J, Pepys MB, et al. (1988) Amyloid P component binds to keratin bodies in human skin and to isolated keratin filament aggregates in vitro. J Invest Dermatol 91: 22–28.
[14]
Hogarth MB, Slingsby JH, Allen PJ, Thompson EM, Chandler P, et al. (1998) Multiple lupus susceptibility loci map to chromosome 1 in BXSB mice. J Immunol 161: 2753–2761.
[15]
Izui S, Kelley VE, Masuda K, Yoshida H, Roths JB, et al. (1984) Induction of various autoantibodies by mutant gene lpr in several strains of mice. J Immunol 133: 227–233.
[16]
Izui S, Higaki M, Morrow D, Merino R (1988) The Y chromosome from autoimmune BXSB/MpJ mice induces a lupus-like syndrome in (NZW × C57BL/6)F1 male mice, but not in C57BL/6 male mice. Eur J Immunol 18: 911–915.
[17]
Manly KF, Olson JM (1999) Overview of QTL mapping software and introduction to map manager QT. Mamm Genome 10: 327–334.
[18]
Merino R, Shibata T, De Kossodo S, Izui S (1989) Differential effect of the autoimmune Yaa and lpr genes on the acceleration of lupus-like syndrome in MRL/MpJ mice. Eur J Immunol 19: 2131–2137.
[19]
Mitchell DA, Pickering MC, Warren J, Fossati-Jimack L, Cortes-Hernandez J, et al. (2002) C1q deficiency and autoimmunity: The effects of genetic background on disease expression. J Immunol 168: 2538–2543.
[20]
Miwa T, Maldonado MA, Zhou L, Sun X, Luo HY, et al. (2002) Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am J Pathol 161: 1077–1086.
[21]
Morel L, Tian XH, Croker BP, Wakeland EK (1999) Epistatic modifiers of autoimmunity in a murine model of lupus nephritis. Immunity 11: 131–139.
[22]
Morel L, Blenman KR, Croker BP, Wakeland EK (2001) The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. Proc Natl Acad Sci U S A 98: 1787–1792.
[23]
Moser KL, Neas BR, Salmon JE, Yu H, Gray-McGuire C, et al. (1998) Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. Proc Natl Acad Sci U S A 95: 14869–14874.
[24]
Obata Y, Tanaka T, Stockert E, Good RA (1979) Autoimmune and lymphoproliferative disease in (B6-GIX+ × 129)F1 mice: Relation to naturally occurring antibodies against murine leukemia virus-related cell surface antigens. Proc Natl Acad Sci U S A 76: 5289–5293.
[25]
O'Keefe TL, Williams GT, Davies SL, Neuberger MS (1996) Hyperresponsive B cells in CD22-deficient mice. Science 274: 798–801.
[26]
O'Keefe TL, Williams GT, Batista FD, Neuberger MS (1999) Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 189: 1307–1313.
[27]
Pepys MB (1974) Role of complement in induction of antibody production in vivo: Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J Exp Med 140: 126–145.
[28]
Pepys MB, Butler PJ (1987) Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. Biochem Biophys Res Commun 148: 308–313.
[29]
Pepys MB, Baltz M, Gomer K, Davies AJ, Doenhoff M (1979) Serum amyloid P-component is an acute-phase reactant in the mouse. Nature 278: 259–261.
[30]
Prodeus AP, Goerg S, Shen LM, Pozdnyakova OO, Chu L, et al. (1998) A critical role for complement in maintenance of self-tolerance. Immunity 9: 721–731.
[31]
Rozzo SJ, Vyse TJ, Drake CG, Kotzin BL (1996) Effect of genetic background on the contribution of New Zealand black loci to autoimmune lupus nephritis. Proc Natl Acad Sci U S A 93: 15164–15168.
[32]
Russell AI, Cunninghame Graham DS, Shepherd C, Roberton CA, Whittaker J, et al. (2004) Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 13: 137–147.
[33]
Santiago ML, Mary C, Parzy D, Jacquet C, Montagutelli X, et al. (1998) Linkage of a major quantitative trait locus to Yaa gene-induced lupus-like nephritis in (NZW × C57BL/6)F1 mice. Eur J Immunol 28: 4257–4267.
[34]
Santiago-Raber ML, Lawson BR, Dummer W, Barnhouse M, Koundouris S, et al. (2001) Role of cyclin kinase inhibitor p21 in systemic autoimmunity. J Immunol 167: 4067–4074.
[35]
Szalai AJ, Weaver CT, McCrory MA, van Ginkel FW, Reiman RM, et al. (2003) Delayed lupus onset in (NZB × NZW)F1 mice expressing a human C-reactive protein transgene. Arthritis Rheum 48: 1602–1611.
[36]
Theofilopoulos AN, Dixon FJ (1985) Murine models of systemic lupus erythematosus. Adv Immunol 37: 269–390.
[37]
Theofilopoulos AN, Kono DH (1999) The genes of systemic autoimmunity. Proc Assoc Am Physicians 111: 228–240.
[38]
Vyse TJ, Todd JA (1996) Genetic analysis of autoimmune disease. Cell 85: 311–318.
[39]
Vyse TJ, Rozzo SJ, Drake CG, Izui S, Kotzin BL (1997) Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand black mice. J Immunol 158: 5566–5574.
[40]
Wakeland EK, Liu K, Graham RR, Behrens TW (2001) Delineating the genetic basis of systemic lupus erythematosus. Immunity 15: 397–408.
[41]
Wu X, Jiang N, Deppong C, Singh J, Dolecki G, et al. (2002) A role for the Cr2 gene in modifying autoantibody production in systemic lupus erythematosus. J Immunol 169: 1587–1592.
[42]
Xie S, Chang SH, Sedrak P, Kaliyaperumal A, Datta SK, et al. (2002) Dominant NZB contributions to lupus in the (SWR × NZB)F1 model. Genes Immun 3: (Suppl 1)S13–S20.
